Clinical Efficacy and Survival Analysis of Chidamide Combined with R-DHAP Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
WANG Xiaowei, LI Ning, LIU Ting, et al
Emergency Center, the Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang Shaanxi 712000
Abstract：【Objective】To explore the efficacy of chidamide combined with R-DHAP regimen in the treatment of relapsed/refractory diffuse large B-cell lymphoma(DLBCL). 【Methods】A total of 78 patients with relapsed/refractory DLBCL were selected and randomly divided into the observation group and the control group. The control group was treated with R-DHAP regimen, and the study group was treated with chidamide combined with R-DHAP regimen. The ECOG score, clinical efficacy, serum vascular endothelial growth factor (VEGF), β2-microglobulin (β2-MG) levels, adverse drug, and progression-free survival time reactions were compared between the two groups. 【Results】After 3 courses of treatment, the ECOG scores of both groups were lower (P<0.05), which the study group showed lower than the control group(P<0.05). The objective remission rate of the observation group was higher than that of the control group (P<0.05). After 3 courses of treatment, the levels of serum VEGF and β2-MG in both groups were lower than those before treatment (P<0.05); And the levels of serum VEGF and β2-MG in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in both groups was not statistically significant (P>0.05). The median progression-free survival curves between the observation group and the control group was 20.60 months and 15.18 months, respectively, which was statistically significant difference (P<0.05). 【Conclusion】Chidamide combined with R-DHAP regimen in the treatment of patients with relapsed/refractory DLBCL can improve clinical symptoms and enhance the curative effect.It can reduce the levels of serum VEGF and β2-MG, prolong the survival time of patients, and it is safe and reliable.
王晓伟, 李宁, 刘婷, 王亚琦. 西达苯胺联合R-DHAP方案治疗复发/难治性弥漫大B细胞淋巴瘤的临床疗效[J]. 医学临床研究, 2024, 41(4): 537-539.
WANG Xiaowei, LI Ning, LIU Ting, et al. Clinical Efficacy and Survival Analysis of Chidamide Combined with R-DHAP Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma. JOURNAL OF CLINICAL RESEARCH, 2024, 41(4): 537-539.
[1] SEHN L H, HERRERA A F, FLOWERS C R, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma[J].J Clin Oncol,2020, 38(2):155-165.
[2] HARRIS L J, PATEL K, MARTIN M. Novel therapies for relapsed or refractory diffuse large B-cell lymphoma [J].Int J Mol Sci,2020, 21(22):8553-8559.
[3] WITZENS-HARIG M, VIARDOT A. The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL - results from the Phase-Ⅱ STORM trial [J].Hemasphere,2021, 5(10):636-643.
[4] 温晓莲, 赵瑾, 苏丽萍. 西达本胺治疗外周T细胞淋巴瘤的临床效果及安全性[J].肿瘤研究与临床, 2020, 32(9):633.
[5] 张璐, 江晓莉, 张治业, 等. 西达本胺联合化疗方案治疗复发/难治性AITL合并自身免疫性溶血性贫血1例并文献复习[J].临床血液学杂志, 2019, 32(1):55-57.
[6] 李军民, 管忠震, 沈悌, 等. 中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志, 2013, 34(9):816-819.
[7] 王树叶, 王晨. 淋巴瘤简明诊疗策略[M]. 北京:人民卫生出版社, 2013:102-103.
[8] 徐应永.疗效评价标准在恶性淋巴瘤临床研究中的应用[J].临床肿瘤学杂志, 2019, 24(3):256-261.
[9] MILLER T P, FISHER B T, GETZ K D, et al. Unintended consequences of evolution of the common terminology criteria for adverse events [J].Pediatr Blood Cancer,2019, 66(7):277-284.
[10] VERCELLINO L, DI BLASI R, KANOUN S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma[J].Blood Adv,2020, 4(22):5607-5615.
[11] THURESSON P O, VANDER VELDE N, GUPTA P, et al.A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large b cell lymphoma [J].Adv Ther,2020, 37(12):4877-4893.
[12] XU L, FENG J, TANG H, et al. Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib [J].Cell Death Dis,2020, 11(4):297-305.
[13] 杨理, 张炜, 张美兰, 等. 西达本胺联合R2-CHOP方案治疗复发难治EZB/C3亚型弥漫大B细胞淋巴瘤一例[J].中华血液学杂志, 2021, 42(5):436-437.
[14] ALBALAWI I A, MIR R, ABU DUHIER F M. Genetic effects of vascular endothelial growth factor A (VEGF-A) and its association with disease progression in breast cancer population of saudi arabia [J].Asian Pac J Cancer Prev,2020, 21(1):139-145.
[15] CHAI D, LI K, DU H, et al. β2-microglobulin has a different regulatory molecular mechanism between ER+ and ER- breast cancer with HER2 [J].BMC Cancer,2019, 19(1):223-239.
[16] GUAN X W, WANG H Q, BAN W W, et al. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20 [J].Cell Death Dis,2020, 11(1):20-26.
2024, Vol. 41 
